These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 28895870

  • 1. Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus.
    Kapczynski DR, Sylte MJ, Killian ML, Torchetti MK, Chrzastek K, Suarez DL.
    Vet Immunol Immunopathol; 2017 Sep; 191():74-79. PubMed ID: 28895870
    [Abstract] [Full Text] [Related]

  • 2. Protective Efficacy of Recombinant Turkey Herpes Virus (rHVT-H5) and Inactivated H5N1 Vaccines in Commercial Mulard Ducks against the Highly Pathogenic Avian Influenza (HPAI) H5N1 Clade 2.2.1 Virus.
    Kilany WH, Safwat M, Mohammed SM, Salim A, Fasina FO, Fasanmi OG, Shalaby AG, Dauphin G, Hassan MK, Lubroth J, Jobre YM.
    PLoS One; 2016 Sep; 11(6):e0156747. PubMed ID: 27304069
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of recombinant H5 vaccines delivered in ovo or day of age in commercial broilers against the 2015 U.S. H5N2 clade 2.3.4.4c highly pathogenic avian Influenza virus.
    Kapczynski DR, Chrzastek K, Shanmugasundaram R, Zsak A, Segovia K, Sellers H, Suarez DL.
    Virol J; 2023 Dec 15; 20(1):298. PubMed ID: 38102683
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy of a Recombinant Turkey Herpesvirus H5 Vaccine Against Challenge With H5N1 Clades 1.1.2 and 2.3.2.1 Highly Pathogenic Avian Influenza Viruses in Domestic Ducks (Anas platyrhynchos domesticus).
    Pantin-Jackwood MJ, Kapczynski DR, DeJesus E, Costa-Hurtado M, Dauphin G, Tripodi A, Dunn JR, Swayne DE.
    Avian Dis; 2016 Mar 15; 60(1):22-32. PubMed ID: 26953940
    [Abstract] [Full Text] [Related]

  • 8. Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus.
    Kapczynski DR, Esaki M, Dorsey KM, Jiang H, Jackwood M, Moraes M, Gardin Y.
    Vaccine; 2015 Feb 25; 33(9):1197-205. PubMed ID: 25613723
    [Abstract] [Full Text] [Related]

  • 9. Vaccine Protection of Turkeys Against H5N1 Highly Pathogenic Avian Influenza Virus with a Recombinant Turkey Herpesvirus Expressing the Hemagglutinin Gene of Avian Influenza.
    Kapczynski DR, Dorsey K, Chrzastek K, Moraes M, Jackwood M, Hilt D, Gardin Y.
    Avian Dis; 2016 Jun 25; 60(2):413-7. PubMed ID: 27309280
    [Abstract] [Full Text] [Related]

  • 10. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
    Kim SM, Kim YI, Park SJ, Kim EH, Kwon HI, Si YJ, Lee IW, Song MS, Choi YK.
    J Virol; 2017 Mar 15; 91(6):. PubMed ID: 28077631
    [Abstract] [Full Text] [Related]

  • 11. Protective efficacy of H5 inactivated vaccines in meat turkey poults after challenge with Egyptian variant highly pathogenic avian influenza H5N1 virus.
    Kilany WH, Abdelwhab EM, Arafa AS, Selim A, Safwat M, Nawar AA, Erfan AM, Hassan MK, Aly MM, Hafez HM.
    Vet Microbiol; 2011 May 12; 150(1-2):28-34. PubMed ID: 21236607
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Examination of the protective efficacy of two avian influenza H5 vaccines against clade 2.3.4.4b H5N8 highly pathogenic avian influenza virus in commercial broilers.
    El-Shall NA, Awad AM, Sedeik ME.
    Res Vet Sci; 2021 Nov 12; 140():125-133. PubMed ID: 34425414
    [Abstract] [Full Text] [Related]

  • 15. Protective efficacy of a prime-boost protocol using H5-DNA plasmid as prime and inactivated H5N2 vaccine as the booster against the Egyptian avian influenza challenge virus.
    Hussein HA, Ahmed BM, Aly SM, El-Deeb AH, El-Sanousi AA, Rohaim MA, Arafa AA, Gadalla MR.
    Acta Virol; 2016 Nov 12; 60(3):307-15. PubMed ID: 27640441
    [Abstract] [Full Text] [Related]

  • 16. Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination.
    Ladman BS, Gelb J, Sauble LA, Murphy MV, Spackman E.
    Avian Pathol; 2019 Aug 12; 48(4):371-381. PubMed ID: 30961360
    [Abstract] [Full Text] [Related]

  • 17. Protection Afforded by a Recombinant Turkey Herpesvirus-H5 Vaccine Against the 2014 European Highly Pathogenic H5N8 Avian Influenza Strain.
    Steensels M, Rauw F, van den Berg T, Marché S, Gardin Y, Palya V, Lambrecht B.
    Avian Dis; 2016 May 12; 60(1 Suppl):202-9. PubMed ID: 27309056
    [Abstract] [Full Text] [Related]

  • 18. Herpesvirus of turkey-vectored avian influenza vaccine offers cross-protection against antigenically drifted H5Nx highly pathogenic avian influenza virus strains.
    Nassif S, Zaki F, Mourad A, Fouad E, Saad A, Setta A, Felföldi B, Mató T, Kiss I, Palya V.
    Avian Pathol; 2020 Dec 12; 49(6):547-556. PubMed ID: 32615785
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The efficacy of recombinant turkey herpesvirus vaccines targeting the H5 of highly pathogenic avian influenza virus from the 2014-2015 North American outbreak.
    Balzli CL, Bertran K, Lee DH, Killmaster L, Pritchard N, Linz P, Mebatsion T, Swayne DE.
    Vaccine; 2018 Jan 02; 36(1):84-90. PubMed ID: 29180030
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.